Endometrial Cancer Clinical Trials (as of August 2, 2021)

ENGOT-en15/MITO

Leading group: MITO

Clinical Trial Study: GOG-F/Merck phase 3 endometrial cancer trial in MSI-H population: pembro vs carbo-paclitaxel

Planned number of patients: TBA

Participating groups:

TBA

Planned start in 3Q 2021

 

ENGOT-en14/DGOG/RAINBO

Leading group: DGOG

Clinical Trial Study: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, the RAINBO plateform trial

Planned number of patients: differs from cohorts

TP53: 420; MSI: 300, NSMP: 600, POLE : 100 

Participating groups:

GINECO, NCRI, CCTG

 

ENGOT-en13/GINECO/DOMENICA

Leading group: GINECO

Clinical Trial Study: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting

Planned number of patients: 142

Participating groups:

BGOG, GEICO, MaNGO, MITO

Planned start in 4Q 2021

 

ENGOT-en12/NOGGO/INCYTE

Leading group: NOGGO

Clinical Trial Study: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Planned number of patients: 220

Participating groups:

BGOG, GINECO, HECOG, MITO

 

ENGOT-en11/BGOG/KEYNOTE-B21

Leading group: BGOG

Clinical Trial Study: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without (Chemo)Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery With Curative Intent

Planned number of patients: 990

Participating groups:

A-AGO, AGO, CEEGOG, GEICO, GINECO, HECOG, ISGO, PGOG, TRSGO, MITO, NCRI, NSGO

 

ENGOT-en10/BGOG/DUO-E

Leading group: BGOG

Clinical Trial Study: A Phase 3 trial with Durvalumab-Olaparib in newly diagnosed advanced and recurrent endometrial cancer

Planned number of patients: 699

Participating groups:

NOGGO, HECOG, ISGO, PGOG, NSGO, CEEGOG

  

ENGOT-en8/GINECO/ROCSAN

Leading group: GINECO

Clinical Trial Study: ROCSAN study: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

Planned number of patients:  63 in phase 1, 170 in phase 2

Participating groups:

AGO, GEICO, MITO

Planned start in 3Q 2019

  

ENGOT-en7/MaNGO/atTEnd

Leading group: MaNGO

Clinical Trial Study: AtTEnd trial: Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Planned number of patients: 550

Participating groups:

GEICO, SAKK, A-AGO, AGO, NCRI, JGOG, ANZGOG, TGOG, KGOG

FPI October 2018

 

ENGOT-en6/NSGO/RUBY (Part II)

Leading group: NSGO

Clinical Trial Study: A phase III, randomized, open-label study of TSR-042, an Anti-PD-1 monoclonal antibody, versus investigator´s choice chemotherapy in patients with advanced/recurrent endometrial cancer

Planned number of patients: 270

Participating groups:

BGOG, CEEGOG, DGOG, ISGO

 

ENGOT-en5/BGOG-en5/SIENDO

Leading group: BGOG

Clinical Trial Study: A randomized phase III trial of maintenance with Selinexor/placebo after combination chemotherapy for patients with advanced or reccurent endometrial cancer

Planned number of patients: 192

Participating groups:

CEEGOG, GEICO, MITO, NOGGO, ISGO